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Abstract
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which
have signiﬁcantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action
from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very speciﬁc
side effect proﬁles. In this review, we summarize these adverse events, provide information on their prevention, and give
practical guidance for monitoring of patients and for management of adverse events.
Introduction
During the last years, options for multiple myeloma have
increased substantially with the introduction of several
immunomodulatory agents (IMiDs), proteasome inhibitors
(PIs), monoclonal antibodies (mAbs), and a histone deace-
tylase inhibitor (HDACi). Inclusion of novel drugs in
myeloma therapy resulted in an increased depth of
responses, improved progression-free and overall survival
with substantial gains in transplant-eligible patients, and
more moderate improvements in elderly patients. The new
drugs differ not only in their mode of action, but impor-
tantly, also in their toxicity proﬁle from previous standard
treatments. Here, we present the most relevant side effects
of the novel drugs reported in pivotal clinical studies and
discuss strategies for their prevention and management.
Methods
Pivotal trials leading to drug approval, and references of all
regimens recommended by the National Comprehensive
Cancer Network (NCCN) clinical practice guidelines on
multiple myeloma, version 1.2018 [1], served as a basis for
the summaries of treatment-emergent adverse events (AEs).
Table S1 of the online supplemental material summarizes
the indications approved in the United States (US) and the
European Union (EU) valid at the time of writing. Tables 1
and S3 summarize the special warnings and precautions
with regard to toxicities of novel agents and common
backbone agents as per US prescribing information (USPI)
and EU summary of medicinal product characteristics (EU
SmPC). These form a patient monitoring guide for com-
plications potentially associated with the approved regi-
mens. All grade ≥3 AEs reported in the pivotal trials leading
to US and/or EU approval and published at the time of
writing are summarized in Table S2A–D. Where clearly
identiﬁed in the drug labels, a distinction was made between
AEs, deﬁned as “…any untoward medical occurrence in a
patient administered a medicinal product and which does
not necessarily have to have a causal relationship with this
treatment” and adverse drug reactions (ADRs), deﬁned as
“…all noxious and unintended responses to a medicinal
product related to any dose…” [2]. When a clear
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classiﬁcation was not available, the event was listed by the
term used in the source document or generally as AE.
The AEs that are discussed in the management section
were selected based on their clinical importance rather than
their incidence. Management recommendations were taken
from available guidelines, such as those developed by the
International Myeloma Working Group [3–5], the European
Myeloma Network [6], the NCCN [1, 7], the British
Committee for Standards in Hematology/United Kingdom
Myeloma Forum [8], from literature referenced in the
respective sections, and from the USPIs and EU SmPCs.
These recommendations are subject to the treating physi-
cian’s best clinical judgment.
Incidence of adverse events
Multiple myeloma shows a wide range of tumor-related co-
morbidities [4, 9] and the majority of patients receive a
number of anti-myeloma drugs and medication to amelio-
rate tumor-associated or other co-morbidities. Thus, it is
frequently impossible to clearly attribute a speciﬁc side
effect to an individual drug. The AEs listed below therefore
should be interpreted in the context of complications of the
disease, of speciﬁc drugs or drug combinations adminis-
tered, and of supportive or prophylactic measures. Of note,
uniform reporting standards for AEs, such as the Medical
Dictionary for Regulatory Activities (MedDRA, www.
meddra.org) or the Common Terminology Criteria for
Adverse Events (CTCAE, https://ctep.cancer.gov/
protocoldevelopment/electronic_applications/ctc.htm), are
not yet consistently used throughout studies, leading to a
substantial variation in the documentation of quality, inci-
dence, and grade of AEs (Table S2A–D).
Warnings and precautions for use of individual drugs as
listed in the respective USPIs and EU SmPCs are shown in
Table 1 (novel agents) and Table S3 (backbone agents) and
provide guidance for patient monitoring during treatment.
Immunomodulatory agents (IMiDs)
The overall incidence of AEs reported in pivotal trials
employing IMiD-based regimens is shown in Table S2A.
All IMiDs are structural analogs of thalidomide and thus
teratogenic. Adequate patient education and contraceptive
measures are therefore mandatory for all three drugs of this
class [10–15].
Thalidomide
In the United States, thalidomide (T)-based therapies are no
longer widely used. In Europe, thalidomide is part of the
VTD regimen for induction therapy before ASCT and
remains an essential element of myeloma therapy in major
regions of the world, like South America, parts of Asia, and
several Eastern European countries. The incidence and
severity of thalidomide-related AEs is dose and treatment
duration dependent and inﬂuenced by potential comorbid-
ities and toxicities of co-medications. Susceptibility for
thalidomide-induced peripheral neuropathy (PNP) has been
linked to polymorphism of genes governing repair
mechanisms and inﬂammation in the peripheral nervous
system [16]. A systematic review revealed somnolence,
constipation, neuropathy, rash, cardiac events, and venous
thromboembolism as the most frequent grade 3 or 4 AEs of
thalidomide single-agent therapy, particularly with doses
>200 mg/day in relapsed/refractory multiple myeloma
(RRMM) [17]. In clinical trials using melphalan and
prednisone in combination with thalidomide (MPT),
hematological events, infections, other neurological
toxicities, PNP, deep vein thrombosis, and dermatological
toxicity were predominant [18, 19]. In addition, arterial
thromboembolism, drowsiness, dizziness, orthostatic
hypotension, neutropenia, thrombocytopenia, increased
HIV viral load, bradycardia, serious dermatological reac-
tions (Stevens–Johnson syndrome and toxic epidermal
necrolysis), seizures, tumor lysis syndrome, and complica-
tions that are more frequent while on contraceptives,
hypersensitivity, and increased risk for secondary primary
malignancies were reported [13].
Patients should be monitored for thromboembolic com-
plications, PNP, rash/skin reactions, bradycardia, arrhyth-
mia, syncope, somnolence, neutropenia, thrombocytopenia,
and others (Table 1) [10, 13].
Lenalidomide
The toxicity proﬁle of lenalidomide (R), although structu-
rally very similar to thalidomide, differs remarkably from
the originator compound (Table S2A). Notably, neuropathy,
constipation, and somnolence are rare, while hematologic
AEs are more frequent [20]. Grade ≥3 neutropenia was
reported in 26% of patients treated with lenalidomide–
dexamethasone (Rd) for 18 cycles and in 28% of those on
continuous Rd in the FIRST trial [21]. Grade ≥3 thrombo-
cytopenia occurred in 8% of patients in either arm. The
most frequent non-hematological grade ≥3 side effects
occurring in the Rd 18 arm in more than 5% were infections
(22%), fatigue (9%), cardiac disorders (7%), venous
thromboembolism (6%), and asthenia (6%). Long-term
lenalidomide therapy may be associated with chronic diar-
rhea [22]. Side effects observed with MPR and MPR fol-
lowed by R maintenance in the MM015 trial [23] were
similar to those reported for the FIRST trial and are listed in
Table S2A. Lenalidomide therapy is associated with an
increased risk for second primary malignancies, especially
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in the post-transplantation setting [24–26], or after a
melphalan-containing regimen [27], and after an IMiD-
based induction therapy [28]. Data from the latter study
show a cumulative incidence of 0.7, 2.3, and 3.8% after 1,
2, and 3 years, with the highest incidence in elderly patients.
Lenalidomide is to a substantial degree excreted by the
kidney and the dose has to be adapted to glomerular ﬁl-
tration rate [29]. Dose modiﬁcations are indicated for grade
3 or 4 neutropenia or thrombocytopenia, and for grade 2 to
3 skin rash.
Patients should be monitored for hematological events,
thromboembolic complications, PNP, infections,
severe skin reactions, diarrhea, secondary malignancies,
allergic reactions, cataracts, and others (Table 1) [11, 14].
Pomalidomide
The most frequently reported grade 3 or 4 ADRs reported
in heavily pretreated patients receiving pomalidomide
were hematological ADRs, including neutropenia, anemia,
and thrombocytopenia (Table S2A). Other severe
ADRs included infections, fatigue, pyrexia, peripheral
edema, and venous thromboembolic events. Cases of
PNP were non-serious, although it is of note that
patients with ongoing grade ≥2 PNP were excluded
from clinical trials with pomalidomide. Modiﬁcations of
pomalidomide dose are indicated for grade 3 or 4 neu-
tropenia or thrombocytopenia, and for grade 2 to 3 skin
rash.
Patients should be monitored for hematological events,
thromboembolic complications, skin rash, infections, PNP,
diarrhea, secondary malignancies, allergic reactions, dizzi-
ness, confusion, and others (Table 1) [12, 15].
Proteasome inhibitors (PIs)
The overall incidence of AEs reported in published pivotal
trials employing PI-based regimens is shown in Table S2B.
Bortezomib
The most commonly reported ADRs occurring during
treatment with bortezomib were neutropenia, thrombocy-
topenia, anemia, PNP (including sensory), herpes zoster,
nausea, diarrhea, constipation, vomiting, fatigue, pyrexia,
headache, paresthesia, decreased appetite, dyspnea, rash,
and myalgia (Table S2B). Dose modiﬁcations are indicated
in response to hematological AEs as well as PNP. Viral
prophylaxis is mandatory and will be discussed in the pre-
vention and management section.
Patients should be monitored for viral re-activation, PNP,
constipation, diarrhea, progressive multifocal leukoence-
phalopathy, seizures, hypotension, posterior reversible
encephalopathy syndrome, heart failure, pulmonary dis-
orders, and others (Table 1) [30, 31].
Carﬁlzomib
Carﬁlzomib is generally very well tolerated. The most
commonly reported ADRs were anemia, fatigue, diarrhea,
thrombocytopenia, nausea, pyrexia, dyspnea, respiratory
tract infection, cough, and peripheral edema (Table S2B).
Other, less frequent, but possibly serious ADRs include
cardiac toxicity, pulmonary toxicities, pulmonary hyper-
tension, hypertension including hypertensive crises, venous
thrombosis, hemorrhage, acute renal failure, tumor lysis
syndrome, infusion reactions, hepatic toxicity, posterior
reversible encephalopathy syndrome, thrombotic thrombo-
cytopenic purpura and hemolytic uremic syndrome (TTP/
HUS), and embryo-fetal risk. Cardiac toxicity and dyspnea
typically occurred early in the course of carﬁlzomib therapy,
predominantly in patients with pre-existing cardiac impair-
ment. Dose modiﬁcations are warranted in response to
hematological AEs or any other severe or life-threatening
non-hematologic toxicity, as well as in patients with
impaired renal function [32, 33].
Patients should be monitored for pre- and postinfusional
hypertension, cardiac, renal and pulmonary toxicities,
diarrhea, tumor lysis syndromes, neutropenia, and throm-
bocytopenia, and others (Table 1) [32, 33].
Ixazomib
Experience with AEs occurring with ixazomib is limited.
The most frequent AEs found to be associated with ixazo-
mib include thrombocytopenia, gastrointestinal toxicities,
PNP, peripheral edema, cutaneous reactions, and hepato-
toxicity (Table S2B). Dose modiﬁcations are recommended
in response to thrombocytopenia, neutropenia, rash, PNP,
and for other non-hematological toxicities at the physician’s
discretion when they reach grade 3 or higher [34, 35].
Patients should be monitored for thrombocytopenia,
neutropenia, nausea, vomiting, diarrhea, constipation, dry
eye, conjunctivitis, and others (Table 1) [34, 35].
Histone deacetylase inhibitors (HDACis)
The overall incidence of AEs reported with panobinostat in
combination with bortezomib and dexamethasone (Pano-
Vd, PANORAMA trial) is shown in Table S2C. The most
frequent hematological AEs included thrombocytopenia,
anemia, neutropenia, and lymphopenia. Non-hematological
AEs included diarrhea, sometimes with signiﬁcant impair-
ment of patients’ well-being, electrolyte imbalances,
increased creatinine, fatigue, decreased appetite, peripheral
edema, pyrexia, nausea, and vomiting. Grade ≥3 PNP was
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reported relatively frequently in this combination (18% in
Pano-Vd versus 15% in placebo-Vd) [36], but the frequency
of this complication would be reduced, if bortezomib was
given by the subcutaneous route, the present standard of
care [36], or if another PI was used. Dose modiﬁcations are
recommended in response to thrombocytopenia, gastro-
intestinal toxicities, neutropenia, and hepatic impairment.
Patients should be monitored for diarrhea, nausea,
infections, cardiac toxicities, blood cell counts, blood
electrolytes, liver and thyroid function, hemorrhage, and
others (Table 1) [37, 38].
Monoclonal antibodies (mAbs)
The overall incidence of AEs reported in published pivotal
trials for mAb-based regimens is shown in Table S2D. The
most frequent AEs are infusion-related reactions (IRR),
usually during the ﬁrst administration, which disappear
thereafter and rarely lead to treatment discontinuation.
Elotuzumab
Apart from IRR, which occurred in 10% of patients
receiving elotuzumab in combination with lenalidomide and
dexamethasone, the most common ADRs were fatigue,
pyrexia, constipation, PNP, diarrhea, herpes zoster, naso-
pharyngitis, cough, pneumonia, upper respiratory tract
infections, lymphopenia, decreased appetite, and weight
loss. Elotuzumab is a humanized IgGk antibody and inter-
feres with response assessment in patients with IgGk M-
component. The most serious ADR was pneumonia.
Patients should be monitored for infusion reactions,
infections, diarrhea, fever, cough, constipation, hepatotoxi-
city, and others (Table 1) [39, 40].
Daratumumab
The most commonly reported ADRs were IRR, which
occurred in approximately half of patients (mostly grade 1
or 2); the majority (95%) of IRR occurred at the ﬁrst
infusion. Other commonly reported ADRs were anemia,
neutropenia, thrombocytopenia, dyspnea, fatigue, pyrexia,
cough, nausea, back pain, pneumonia, and upper respiratory
tract infections (Table S2D). Daratumumab interferes with
blood group serological testing, as it binds to CD38 on red
blood cells and results in a positive indirect antiglobulin test
(indirect Coombs test) [41, 42]. Due to its nature as an IgGk
antibody, it may interfere with response assessment in
patients with an IgGk M-component [43] and also with
minimal residual disease assessment, because it binds to
CD38-positive residual myeloma cells thus precluding
detection of CD38-positive cells by diagnostic anti-CD38
antibodies as recommended by EUROFLOW for
conventional ﬂow cytometry [44]. A subcutaneous pre-
paration is in clinical testing and will allow much faster
administration with signiﬁcantly reduced incidence of side
effects.
Patients should be monitored for IRR, nausea, fever,
cough, upper respiratory tract infection, neutropenia,
thrombocytopenia, and others (Table 1) [41, 42].
Backbone agents
Backbone agents frequently used in doublet or triplet
combinations with novel agents are dexamethasone,
cyclophosphamide, prednisone, doxorubicin, and melpha-
lan. Table S3 shows potentially occurring toxicities of these
chemotherapy and corticosteroid backbone agents as per
USPI/EU SmPC. The NCCN does no longer consider
melphalan-containing regimens as the standard of care to
treat patients with multiple myeloma, because of their
potential to induce signiﬁcant cytopenias and subsequently
limit the use of novel agents [1], but melphalan continues to
be a valuable backbone in non-US countries to which novel
agents are added.
Prevention and management of adverse
events
In multiple myeloma, it is not always possible to dis-
criminate whether complications occur as a consequence of
drug treatment, of the disease itself, or due to a combination
of both. Furthermore, a combination of drugs is usually
administered. AEs therefore need to be considered in the
context of this complex situation. Nevertheless, it is critical
to carefully monitor patients regarding possible side effects
(Table 1 and Tables S2A–D and S3) to avoid early com-
plications that may compromise therapeutic outcome.
Hematological toxicities are commonly observed with most
novel agents, but as their prevention and management is
quite similar independent of the drugs used, we will not
discuss this in detail here [3, 6].
Thromboembolic complications
Treatment-, patient-, and myeloma-speciﬁc risk factors for
thromboembolic complications, which are quite frequent in
multiple myeloma [8, 45], are shown in Table 2. Throm-
boembolic events occur more frequently during the initial
phase of treatment and less commonly during episodes of
well-controlled disease, in remission, or at relapse [46].
IMiDs alone and particularly in combination with dex-
amethasone and other drugs, such as carﬁlzomib [32, 33],
erythropoietin, or adriamycin, are associated with an
increased risk of thromboembolic events [10–15].
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Modiﬁable risk factors should be minimized if possi-
ble. Patients with one patient-speciﬁc risk factor for
thromboembolism should receive thromboprophylaxis
with aspirin at a dose of 81–325 mg [1, 4, 8, 46], while
those with two patient-speciﬁc or one treatment-speciﬁc
risk factors should be treated either with low molecular
weight heparins (LMWH) or warfarin, (Table 2) [1, 4, 8,
10–15, 46]. However, there is currently no robust evi-
dence on the optimal duration of thromboprophylaxis,
especially in active uncontrolled disease as well as in
lenalidomide maintenance therapy. Concomitant admin-
istration of erythropoietic agents or other drugs known to
increase the risk of thrombosis, such as hormone repla-
cement therapy, should be used with caution [11]. If a
patient experiences thromboembolic complications, anti-
myeloma treatment may temporarily be discontinued and
anticoagulation therapy started using adjusted dose war-
farin or LMWH, and appropriate monitoring should be
applied. The appropriate initial therapy in the outpatient
setting is therapeutic doses of LMWH. In hospitalized
patients, unfractionated heparin for a minimum of 5 days
may be preferred [8]. Treatment with LMWH or coumarin
should be continued for several months with lower doses
of LMWH. In patients started on intravenous heparin,
therapy should be resumed until the patient’s partial
thromboplastin time (PPT) has increased by 1.5–2.0-fold
compared to control for two consecutive days and then
switched to oral warfarin or coumarin. Once the acute
thromboembolic event has stabilized, anti-myeloma ther-
apy can be restarted depending upon a beneﬁt-risk
assessment with continued anticoagulation therapy with
warfarin or LMWH. Alternatively, anti-myeloma therapy
should be changed to a regimen with lower risk of
thromboembolic complications. Renal failure with GFR
<30 ml/min limits the use of LMWH, since these drugs
depend on renal clearance for drug elimination and
increased blood levels increase the risk of bleeding [47].
Whether the occurrence of thromboembolic complica-
tions is associated with increased mortality in multiple
myeloma is still controversial. Shorter survival was reported
in patients with early thrombotic events (within 6 months
after start of initial therapy or within the ﬁrst 2 years) while
in another study no difference in mortality was noted, nei-
ther in newly diagnosed nor in relapsed/refractory mye-
loma. New oral anticoagulants (NOACs), which include
dabigatran, rivaroxaban, apixaban, and edoxaban, have
been shown to be useful for initial and extended VTE
treatment [48]. These drugs have not systematically been
Table 2 Risk assessment model for the management of venous thromboembolism in multiple myeloma patients (adapted from Palumbo 2008 [46])
Risk factor Recommendation for prophylaxis
Patient-related risk factor
Obesitya
History of VTE
Central-venous catheter or pacemaker For patient-, myeloma- and other medication-related risk factors:
Comorbiditiesb
Inherited thrombophilia or blood clotting disorders If one risk factor, aspirin 81-325 mg, once daily;
Surgical proceduresc if two or more risk factors are present, LMWH
Myeloma-related risk factors (equivalent of enoxaparin 40 mg once daily) or
Active uncontrolled disease full-dose warfarin (target INR 2–3)
Hyperviscosity
Other medication-related risk factors
Erythropoietin
Myeloma medication-related risk factors For myeloma medication-related risk factors:
IMiDs
High-dose dexamethasoned LMWH (equivalent of enoxaparin 40 mg once daily)
Doxorubicin or full-dose warfarin (target INR 2–3)
Multiagent chemotherapy
LMWH low molecular weight heparin, IMiDs immunomodulatory agents, INR international normalized ratio, VTE venous thromboembolism
aDeﬁned as a body mass index ≥30 kg/m2
bComorbidities include diabetes, infections, cardiac diseases, chronic renal disease, and immobilization
cSurgical procedures include general surgery, any anesthesia, trauma, vertebroplasty, and kyphoplasty
d≥480 mg/month
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studied in myeloma as yet, therefore speciﬁc recommen-
dations cannot be made at this point in time.
Peripheral neuropathy
PNP is deﬁned as any form of damage, inﬂammation, or
degeneration of peripheral nerves [49] and can be induced
by IMiDs, some PIs, and HDACis (Table 1 and
Table S2A–C). Thalidomide can cause severe, mostly
irreversible PNP, with higher risk in patients with pre-
existing PNP [10–14, 50]. Among PIs, bortezomib was
shown to induce severe PNP [30, 31]. Bortezomib-induced
neurodegeneration occurs via a proteasome-independent
mechanism and therefore is not considered a group effect of
PIs [51].
The incidence of thalidomide-induced PNP (TiPNP) is
dependent on dose, treatment duration, and patient-speciﬁc
factors, and presents as a sensory neuropathy with promi-
nent symptoms of paresthesia in the hands and feet (glove-
and-stocking distribution) [49, 52, 53]. TiPNP also includes
numbness, and mild motor involvement with muscle cramps
and weakness [49]. Dose reductions are recommended in
patients with grade 1 TiPNP with no loss of function, dose
reduction, or treatment interruption in patients with grade 2,
interfering with function but not with activities of daily
living, and treatment discontinuation in patients where
lower-grade TiPNP does not resolve upon dose modiﬁca-
tions and in patients with grade 3 or 4 TiPNP (Table 3) [10,
13, 54]. Recommendations include patient monitoring at a
monthly interval for the ﬁrst 3 months of treatment to detect
early signs of TiPNP and to continue regular monitoring
during the entire treatment duration.
Bortezomib-induced PNP (BiPNP) is predominantly
sensory, with symptoms of paresthesia and numbness in
distal areas, particularly in the lower limbs. BiPNP char-
acteristically shows prominent small ﬁber involvement,
characterized by sharp, burning pain in the toes and soles of
the feet. Damage of the autonomic nervous system,
including orthostatic hypotension, suppressed heart rate
variability, and delayed gastric emptying, may occur. Motor
neuropathy is uncommon [53]. There are clear guidelines
for the treatment of BiPNP (Table 3) [54]. In case of BiPNP
grade 1 with pain or grade 2, the bortezomib dose should be
reduced to 1.0 mg/m2 twice weekly or the treatment interval
should be extended to 1.3 mg/m2 once per week. In case of
grade 2 with pain or grade 3 BiPNP treatment should be
withheld until symptoms have resolved, then treatment can
be re-initiated at a dose of 0.7 mg/m2 once per week. In the
case if BiPNP of grade 4 treatment must be discontinued
[30, 31]. Intravenous administration of bortezomib leads to
10-fold higher peak plasma levels and to higher rates of
BiPNP than subcutaneous administration. Subcutaneous
administration therefore reduces the incidence of BiPNP,Ta
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particularly BiPNP of grade 3 or 4, without compromising
the anti-myeloma effect and thus should be the preferred
mode of administration [55].
Treatment of symptoms of PNP and neuropathic pain
remains unsatisfactory and includes anti-convulsive
agents (gabapentin and pergabalin) and antidepressants
[3, 4, 8]. Other agents, such as acetyl-L-carnitine and
alphalipoic acid, have shown activity in treatment of
chemotherapy-emergent PNP of other cancers [54]. In
case of neuropathic pain, the three-step ladder of pain
management in cancer patients issued by the World
Health Organization (WHO) should be followed [56].
These recommend an escalating analgesic therapy that
includes opioids, such as tapentadol for very severe neu-
ropathic pain. Topical pain medications include lidocaine
and capsaicin [57]. Both, TiPN and BiPN, can also be
associated with autonomic symptoms induced by damage
to small ﬁbers. These include orthostatic hypotension,
sexual dysfunction, constipation, and bradycardia [49]. In
rare cases, the insertion of a pacemaker should be con-
sidered [58, 59]. Recommendations for orthostatic dys-
regulation consist of a combination of vasoconstrictor
drugs, volume expansion, compression garments, and
postural adjustment, together with reduction or dis-
continuation of any concomitant blood pressure lowering
medication. Drugs such as midodrine, pyridostigmine,
and ﬂudrocortisone can be administered, and physical
inactivity should be avoided [60].
Muscle cramps and seizures
Several drugs such as lenalidomide, thalidomide, PIs, and
dexamethasone can induce subtle perturbations of muscle
ﬁbers and/or of neurogenic structures, but the detailed
pathogenesis of muscle cramps is still unknown [49]. Pre-
sently, speciﬁc treatment recommendations are not avail-
able. General suggestions include ﬂuid hydration,
normalizing magnesium and potassium levels, use of mus-
cle relaxants, and moving and stretching the affected areas.
However, the efﬁcacy of these measures has not been
ascertained in clinical trials.
Prophylaxis and treatment of infections
Recommendations on antimicrobial prophylaxis and vacci-
nation are summarized in Tables 4 and 5.
Viruses
Almost all people harbor latent virus infections that nor-
mally are effectively controlled by the host’s immune sur-
veillance system. Bortezomib, other PIs, high-dose
dexamethasone or chemotherapy, and autologous stem cellTa
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transplantation inhibit speciﬁc T cell functions important for
curbing latent virus infections enabling their reactivation,
which may result in severe clinical complications [61].
Caregivers and patients should be aware of the increased
risks inferred by immunosuppression and install appropriate
prophylactic measures, if available.
Vaccination
Patients should be vaccinated against several pathogens
(Table 4). The most important are inﬂuenza virus, pneu-
mococci, and haemophilus inﬂuenzae. A trivalent or
quadrivalent inﬂuenza vaccine should be used in patients,
partners, and caregivers. Vaccination against pneumo-
cocci should be started with a 13-valent vaccine (PCV13)
and followed at least 8 weeks later by a dose of PCV23
(23 valent polysaccharide conjugate) [62]. A herpes zoster
vaccine is currently being studied in patients with multiple
myeloma, but results have not been made available to date
[63]. Present herpes zoster vaccines are live vaccines and
controversy exists whether they can be offered to patients
with well-controlled disease. As an alternative to live-
attenuated vaccines, which are contraindicated for
immunocompromised individuals, heat-inactivated var-
icella zoster vaccines, and recombinant subunit vaccines
have been studied [64–66]. Patients and nonimmune close
contacts traveling or living in areas of high endemicity of
hepatitis B and hepatitis A should receive recombinant
hepatitis B and A vaccine. Response to vaccines fre-
quently is suboptimal in multiple myeloma, making it
desirable to evaluate the efﬁcacy of the vaccination. An
individual report shows that repeated vaccinations with
the same inﬂuenza vaccine enhances anti-vaccine anti-
body production [67]. Ideally, patients should already be
vaccinated in the premalignant state, namely when pre-
senting with high-risk MGUS or SMM or, when feasible,
during periods of optimal disease control.
Hepatitis B and C
Patients living in regions with high prevalence of hepatitis
as well as those with increased alanine transaminase
should be screened using serologic tests (HBsAg, anti-
HBc, and anti-HBs) for previous exposure, or ongoing
infection, and/or reactivation. Preemptive antiviral pro-
phylaxis with nucleoside/nucleotide analogs should be
considered in patients with latent or previous HBV
infection [68]. Formal recommendation for those with a
high risk of HCV infection or with previous infections are
not available, but it seems reasonable to screen the high-
risk group (anti-HCV and/or HCV RNA) and to treat
those with evidence of active infection with modern
direct-acting antivirals.
Herpes zoster
Pain, scarring, and post-herpetic neuralgia are the most
common morbidities associated with herpes zoster reacti-
vation. In pivotal trials, herpes zoster infection occurred in
3–13% of patients receiving bortezomib monotherapy
(Table S2B) [30, 31]. Therefore, antiviral prophylaxis dur-
ing the entire duration of treatment with any of the available
PIs, but also during treatment with mAbs, is mandatory [7].
Antiviral agents such as acyclovir, valaciclovir, and penci-
clovir can be used; valaciclovir and penciclovir have greater
bioavailability than acyclovir making them particularly
suitable for outpatient treatment [69]. Valaciclovir was
shown to signiﬁcantly reduce the incidence of post-herpetic
neuralgia [70], but randomized controlled trials comparing
the efﬁcacy of the various agents are not available. In the
case of overt viral disease, anti-myeloma therapy should be
interrupted and antiviral therapy be intensiﬁed. Upon
symptom relieve, anti-myeloma therapy can be continued,
but a risk of renewed virus reactivation remains [7].
Cytomegalovirus
PIs and high-dose therapy increase the risk for cytomega-
lovirus (CMV) reactivation or infection. Such infections not
rarely remain unrecognized. For diagnosis of CMV infec-
tion, polymerase chain reaction (PCR) technology should be
used, because antibody testing may fail due to impaired
antibody production. CMV prophylaxis is generally not
recommended in multiple myeloma [71], but may be con-
sidered in selective cases with repeated CMV reactivation.
In case of active infection, therapy is typically initiated with
intravenous ganciclovir. For second-line treatment or in
case of poor tolerance or resistance to ganciclovir, foscarnet
and cidofovir can be used [7]. Several new drugs (mar-
ibavir, brincidofovir, and letermovir) are undergoing clin-
ical trials. Oral valgancyclovir is convenient, usually well
tolerated and an option for initial therapy in very ﬁt patients
and for prevention of recurrence of infections during peri-
ods of aggressive therapy. Treatment should be continued at
minimum until a negative PCR test result.
Bacteria and fungi
The risk for bacterial infections is signiﬁcantly higher
compared to the normal population [72], and particularly
high in patients with active disease after start of initial
therapy [73], and in those with a history of frequent infec-
tions and in elderly frail patients. Grade 3 and 4 infections
were noted in 29% of patients treated with continuous
lenalidomide–dexamethasone [21] and in 16.5% of
relapsed/refractory myeloma exposed to carﬁlzomib–
lenalidomide–dexamethasone [74]. Hence, antibiotic
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prophylaxis with either trimethoprim–sulfamethoxazole,
amoxicillin, or a quinolone should be considered for the
ﬁrst months after start of therapy in selected patients with
high risk for bacterial infections such as very elderly
patients, those with a history of several previous infections,
and those exposed to regimes with a high risk of infectious
complications.
Intravenous immunoglobulin is an additional option, but
evidence from randomized studies supporting its efﬁcacy is
scarce. Chapel et al. showed a signiﬁcant beneﬁt with fewer
infections and no sepsis by administration of 400 mg/kg
intravenous immunoglobulin in patients with plateau phase
[75]. A meta-analysis including nine small studies on
intravenous immunoglobulins in patients with chronic
lymphocytic leukemia (CLL) or multiple myeloma revealed
a 55% decrease in major infections with active therapy, but
no effect on overall survival [76]. Taken together, intrave-
nous immunoglobulin prophylaxis may be considered in
selected patients with a history of frequent bacterial infec-
tions independent on whether they present with humoral
immunoparesis, and in patients with an ongoing severe
bacterial infection with no or slow response to standard
antibiotic therapy.
Data on the incidence of pneumocystis jirovecii infec-
tions during treatment with novel drugs are scarce. The risk
increases with severe suppression of T cell immunity. In
case of established infection, the treatment of choice is
trimethoprim–sulfamethoxazole. Other options are dapsone,
atovaquone, or pentamidine [1].
Severe skin reactions
Monitoring patients for severe skin reactions is recom-
mended in patients receiving thalidomide, lenalidomide,
pomalidomide, or ixazomib (Table S2A–D). For limited,
localized rash, antihistamines or topical steroids are
recommended. In case of mild but extensive rash, a short
course of low-dose prednisone should be considered [77].
In patients with grade 2 or 3 skin rash, treatment should be
interrupted or discontinued and reinstated in case of com-
plete resolution. Rarely, severe skin reactions such as
Steven–Johnson syndrome or even toxic dermal necrolysis
have been reported [10, 11, 13, 14, 34]. In such severe
cases, treatment should be permanently discontinued. For
lenalidomide, a desensitization scheme with progressively
increased doses and dosing frequencies to reach a target
dose of 10 mg/day over the course of 6 weeks has been
proposed [78]. Patients having experienced skin reactions
during previous courses of thalidomide treatment should not
receive lenalidomide [11, 14] or in case of limited alter-
natives should be started at a low dose and carefully be
monitored. For patients developing grade 2 or 3 rash during
therapy with ixazomib in combination with lenalidomide,
lenalidomide should be withheld until recovery or
improvement of rash to grade 1. Lenalidomide treatment
can be resumed at the next lower dose. If grade 2 or 3
reappears, withhold both until rash recovers to grade 1 or
lower. Following recovery, resume ixazomib at the next
lower dose and resume lenalidomide at the last dose. In case
of grade 4 toxicity discontinue both drugs [34].
Diarrhea
Diarrhea is a common side effect of novel drugs, and more
frequently observed during exposure with bortezomib,
lenalidomide, and panobinostat. Diarrhea in general was
rare in patients exposed to continuous Rd (4%) or Rd18
(3%) in the FIRST study [22]. However, long-term therapy
with lenalidomide may, after a long asymptomatic period,
induce a speciﬁc form of diarrhea, the so-called bile salt
malabsorption syndrome, which seems to result from
damage of the intestinal mucosa. Increased accumulation of
bile acids in the small bowel may lead to debilitating epi-
sodes of diarrhea that may severely impair the patients’
quality of life [22]. The diagnosis can be established by
non-invasive selenium homocholic acid taurine (SeHCAT)
scanning or is supported when treatment with bile acid
binders such as colesevelam results in improvement of
symptoms [79]. Following the diagnosis, dietary fat intake
should be reduced (to 20% of total calories) and/or cole-
sevelam prescribed. Usually, up to 6 × 625 mg in split doses
with food per day lead to rapid improvement in bowel
movements and diarrhea if bile acid malabsorption is the
underlying cause [79].
Panobinostat was also shown to induce gastrointestinal
side effects, particularly diarrhea, which is observed in up to
40% of patients. These events should be managed with
liberal use of antidiarrheal medication, proper hydration,
and antiemetics, if accompanied by emesis and nausea. The
frequency of diarrhea may also be improved through
appropriate dose modiﬁcations of panobinostat and/or bor-
tezomib [36] or by combining the drug with other PIs.
Pharmacological treatment of diarrhea resulting from
anti-myeloma treatment is based primarily on the empirical
use of locally active opioids, such as loperamide, deodor-
ized tincture of opium, and a combination of diphenoxylate
plus atropine [80, 81]. Octreotide, a long-acting somatos-
tatin analog, is generally reserved for use in complicated
cases or as a second-line treatment for persistent diarrhea
after loperamide [81]. In addition, existent dehydration and/
or mineral loss should be compensated.
Renal toxicity
The renal toxicities that have been reported for lenalido-
mide, pomalidomide, bortezomib, carﬁlzomib, and
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elotuzumab are summarized in Table 6. Presently, there is
insufﬁcient data for panobinostat to provide evidence-based
information on its renal toxicity and required dose adjust-
ments in patients with pre-existing renal impairment. For
lenalidomide and ixazomib dosing, recommendations have
been issued for different levels of renal impairment. Lena-
lidomide should be dosed at 5 mg/day in end stage renal
failure, at 15 every other day (or 7.5 mg/day) in patients
with GFR <30 ml/min and at 10 mg/day in those with GFR
30–50 ml/min [11, 14]. Ixazomib should be used at a dose
of 3 mg/week in patients with creatinine clearance of <30
ml/min [34, 35]. Pomalidomide can be administered with-
out dose reduction to patients with moderate and severe
renal impairment [82].
Cardiac and vascular toxicities
Cardiac toxicity has been reported with IMiDs and PIs.
Carﬁlzomib is associated with a higher risk for cardiotoxic
adverse events, including hypertension, shortly after drug
infusion. The exact mechanism has not yet been clariﬁed,
but an effect of carﬁlzomib on endothelial cells and a
common acute rise in NT-proBNP has been reported [83].
A decline in ejection fraction in few patients was shown
[83, 84]. In the ENDEAVOR study, events of heart failure
and pulmonary hypertension were more frequently reported
in Kd versus Vd patients and similar ﬁndings were also
reported in the CLARION study comparing KMP with
VMP [85]. Reported reductions in left ventricular ejection
fraction were mostly reversible. The utility of echocardio-
graphy as a tool to identify patients at risk of reduced left or
right ventricular function was found to be limited in patients
receiving carﬁlzomib [86].
Important cardiopulmonary risk factors and recommen-
dations for patient monitoring, as well as the prevention and
management of such events are shown in Table 7. Patients
with pre-existing cardiac disease and those aged 75 years or
older are at higher risk for carﬁlzomib-induced cardiac
toxicity. They should be subjected to a comprehensive
medical assessment prior to carﬁlzomib initiation [32, 33,
87]. Before administration of carﬁlzomib, their blood
pressure should be tightly controlled and should not exceed
systolic levels above 140 mmHg. In addition, adherence to
30-min infusion time is recommended. Shortening the
infusion time to 10 min after 1–2 cycles can be considered,
if there were no cardiac or pulmonary symptoms [88]. In
case of grade 3 or 4 cardiac events, carﬁlzomib should be
interrupted until recovery. Carﬁlzomib may be restarted at
reduced dose after a thorough beneﬁt/risk assessment [32,
33] and the patient should be assessed for ﬂuid overload
Table 6 Known renal toxicities and dosing recommendations according to USPI/EU SmPC
Published toxicitiesa CKD dose adjustment ESRD dose adjustment
IMiDs
Thalidomide TLS No No
Lenalidomide AKI, AIN, Fanconi syndrome,
minimal change disease, TLS
30 to < 50 ml/min CrCl: 10 mg
daily
<30 ml/min CrCl (HD):
5 mg daily after HD
<30 ml/min CrCl (NOD): 7.5
mg/day or 15 mg every 48 h
End stage renal failure: 5 mg/
day (on dialysis days after
dialysis)
Pomalidomide AKI, crystal nephropathy, TLS No Dose after dialysis
PIs
Bortezomib TMA, TLS No Dose after dialysis
Carﬁlzomib TMA, TLS, ATN No Dose after dialysis
Ixazomib TLS None in mild to moderate
CKD, if < 30 ml/min CrCl
(NOD): 3 mg/week
<30 ml/min CrCl
(HD) including ESRD:
3 mg/week
HDACis
Panobinostat None reported No Insufﬁcient data
mAbs
Elotuzumab AKI No No
Daratumumab None reported No No
AIN acute interstitial nephritis, AKI acute kidney injury, ATN acute tubular necrosis, TMA thrombotic microangiopathy, CKD chronic kidney
disease, CrCl creatinine clearance, ESRD end-stage renal disease, GFR glomerular ﬁltration rate, HD hemodialysis, NOD not on dialysis, TLS
tumor lysis syndrome
aAdapted from Wanchoo et al. [98]
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[87, 88]. A cardiologist should be involved to address the
clinical issue [87, 88]. Currently, a clear dose effect of
cardiac toxicity has not been demonstrated, but it seems
prudent to start with a lower dose in elderly patients (aged
>75 years) and in those with a history of mild cardiac dis-
ease. Patients with more severe heart disease have been
excluded from clinical studies.
Infusion-related reactions
Both approved monoclonal antibodies, elotuzumab and
daratumumab, are of IgG1κ isotype, the former being
humanized and the latter being fully human. In spite of
their similarity with human IgG, treatment with these
antibodies may results in infusion reactions that mostly
are seen during the ﬁrst and less so during following
infusions. Lonial et al. reported infusion-related AEs in
only 10% of patients receiving 20 mg/kg of elotuzumab,
all of grade 1 or 2 [89]. Single-agent daratumumab
resulted in higher rates of infusion-related AEs of 45% as
reported in a phase II study, with only few being classiﬁed
as grade 3 [90].
For both drugs, prophylactic measures are recommended.
Forty-ﬁve to 90 min before start of elotuzumab infusion,
dexamethasone (8 mg, IV), diphenhydramine (25–50 mg
orally or IV) or equivalent, ranitidine (50 mg IV or 150 mg
orally) or equivalent, and paracetamol/acetaminophen
(650–1000 mg orally) should be administered. A similar
regimen should be used ~1 h before daratumumab infusion,
consisting of 100 mg of IV methylprednisolone or equiva-
lent (may be reduced to 60 mg thereafter), oral antipyretic
(paracetamol 650–1000 mg), oral or IV antihistamine
(diphenhydramine 25–50 mg) or equivalent. All patients
should receive post-infusion treatment with 20 mg methyl-
prednisolone or equivalent on each of the 2 days following
infusion. Special precautions need to be taken in patients
with pre-existing chronic obstructive pulmonary disease
(COPD). Premedication with 10 mg montelukast, an oral
leukotriene receptor antagonist, 30 min before dar-
atumumab should be considered as well as post-infusion
Table 7 Carﬁlzomib-related cardiopulmonary adverse events: Table 7A. Recommendations for patient monitoring, Table 7B. Recommendations
for their prevention and management
7A. Patient monitoring 7B. Prevention and management [87, 88]
Life style risk factors Control blood pressure
Smoking
Obesity
Sedentary habit
Before carﬁlzomib therapy to <140/90 mmHg. RAAS inhibitors (ACE
or angiotensin receptor 2 inhibitors) preferred, if needed combine with
calcium channel blockers and/or diuretics, and, thirdly, beta blockers
Age Monitor ﬂuid intake
Biological age ≥75 years Appropriate hydration prior carﬁlzomib dosing in cycle 1 as preventive
measure of tumor lysis syndrome or renal toxicity. If high risk for
cardiotoxic AEs, volume may be reduced to 250 ml even at ﬁrst dose and
thereafter
Comorbidity
Hypertension
Peripheral vascular disease
Diabetes
Hypercholesterolemia
Thromboprophylaxis
Use thromboprophylaxis, if carﬁlzomib is given in combination with
IMiDs or at doses >27 mg/m2
Cardiac risk factors Monitor cardiovascular function
Heart failure (with/without reduced LVEF) Blood pressure (24 h monitoring in special cases), heart rate (ECG),
signs of cardiac failure, ischemia, dyspnea, volume overloadCoronary artery disease (angina, previous MCI or interventions for
CAD)
Valvular heart disease with LV impairment or LV hypertrophy
Hypertrophic, dilated, or restrictive cardiomyopathy
Uncontrolled cardiac arrhythmia (AF or ventricular tachyarrhythmia)
Pretreatment with cardiotoxic agents (anthracyclines), concurrent
treatment with high dose dexamethasone or other anti-myeloma drugs
Intervention in case of cardiac AEs
If grade ≥3 cardiovascular events, withhold carﬁlzomib Stop ﬂuid
administration
Consider restarting carﬁlzomib therapy at 1 dose level reduction (KRd:
27 mg/m2 → 20 mg/m2 → 15 mg/m2, Kd: 56 mg/m2 → 45 mg/m2 → 36
mg/m2 → 27 mg/m2) based on a beneﬁt/risk assessment, particularly if
non- or less cardiotoxic alternatives are not available
When resuming therapy, consider follow-up echocardiograms
(predictive value uncertain [86], but treatment should be withheld in case
of decrease in LVEF) and of biomarkers such as BNP or NT-pro-BNP
(transient increase frequent after carﬁlzomib, if permanent signiﬁcant
increase, withhold carﬁlzomib)
An infusion duration of at least 30 min is highly recommended for
carﬁlzomib independent of dose [88]
ACE angiotensin-converting-enzyme, AEs adverse events, AF arterial ﬁbrillation, BNP brain natriuretic peptide, CAD coronary artery disease, ECG
electrocardiogram, Hg mercury, hr hour, IMiDs immunomodulatory drugs, LV left ventricular, LVEF left ventricular ejection fraction, MCI
myocardial infarction, NT-pro-BNP N-terminal BNP precursor, RAAS renin angiotensin aldosterone system
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therapy with short- and long-term bronchodilators and
inhaled corticosteroids; patients with COPD stage IV dis-
ease should be excluded from daratumumab therapy [91].
An early report showed that an SC preparation of dar-
atumumab can be safely administered within 30 min with a
signiﬁcantly lower rate of daratumumab-related IRRs [92].
Details of dilution volume of the drugs, infusion rates,
increments in rates, and maximum speed are listed in
Table 8.
In case of occurrence of infusion-related AEs of grade
≥2 during elotuzumab infusion, the infusion must be
interrupted and can be restarted at lower infusion rate
(0.5 ml/min) with gradual increase by 0.5 ml/min
every 30 min as tolerated to the rate at which the IRR
occurred. If this is well tolerated, escalation of the infu-
sion rate can be resumed. Patients with a grade ≥3 IRR
may require emergency treatment and permanent dis-
continuation. A similar procedure is recommended for
daratumumab-induced IRR. The infusion should be
interrupted at any grade/severity. If grade 1–2 IRR
occurs, the infusion may be resumed at half the rate at
which it occurred, provided the patient is stabilized; in
case of no recurrence of IRR, escalation can be resumed.
If grade 3 IRR occurs, once IRR decreases to grade ≤2,
the infusion may be restarted at no more than half the rate
at which the IRR occurred. If no recurrence of IRR,
escalation can be resumed. Patients have to discontinue
daratumumab therapy in case of grade 4 (life threatening)
IRRs at ﬁrst or subsequent infusion.
Teratogenicity
Almost all novel agents and backbone agents showed a
certain embryo-fetal risk, especially the thalidomide analogs
of the IMiD group (Table 1 and S2A). Pregnancy must be
excluded before start of treatment. Women of reproductive
potential and their partners should be informed about the
embryo-fetal risk of the respective drugs and about adequate
contraceptive measures. To prevent pregnancy, continuous
abstinence from heterosexual intercourse or two reliable
methods of contraception must be used. The respective
USPIs and EU SmPCs have detailed instructions suited to
the agents used.
Conclusions
A number of novel drugs have recently been introduced in
the treatment of multiple myeloma. These drugs differ in
their mode of action and their side effect and safety proﬁle.
Knowledge of their potential risks and of established mea-
sures to prevent occurrence of complications is essential for
preventing severe symptoms, dose reductions, and/or
treatment discontinuations and in some patients even
Table 8 Prevention and treatment of monoclonal antibody-related infusion reactions
Elotuzumab [39, 40] Daratumumab [41, 42]
Timing 45–90 min prior to infusion Approx. 1 hr. prior to infusion
Premedication Dexamethasone (8 mg IV)
H1 blocker: diphenhydramine (25–50 mg orally or IV)
or equivalent
H2 blocker: ranitidine (50 mg IV or 150 mg orally) or
equivalent
Paracetamol/acetaminophen (650–1000 mg orally)
IV corticosteroid (methylprednisolone 100 mg) or equivalent dose of
an intermediate-acting or long-acting corticosteroid
Oral antipyretic (paracetamol 650–100 mg)
Oral or IV antihistamine (diphenhydramine 25–50 mg) or equivalent
Consider montelukast prior to ﬁrst infusion [91]
Following the second infusion, the dose of IV corticosteroid may be
reduced (methylprednisolone 60 mg)
Post-infusion
medication
Oral corticosteroid (methylprednisolone 20 mg) or equivalent on each
of the 2 days following all infusions. If daratumumab is used in
combination with other drugs, a corticosteroid dose should be
considered on the day after infusion. In those receiving a corticostreoid
dose on day plus one, subsequent dosing may be omitted.
In patients with a history of obstructive pulmonary disorder: use post
infusion medication including short- and long-acting bronchodilators
and inhaled corticosteroids
Treatment If grade ≥2 IRR occurs, infusion must be interrupted
Monitor vital signs every 30 min for 2 hr.
Upon resolution to grade ≤1, restart administration at
0.5 mL/min with gradual increase at a rate of 0.5 mL/
min every 30 min as tolerated to the rate at which IRR
occurred; if no recurrence of IRR, escalation can be
resumed
Grade ≥3 IRR may require permanent discontinuation
and emergency treatment
For IRRs of any grade/severity immediately interrupt infusion
If grade 1–2 IRR occurs, once patient is stabilized, resume infusion at
half the rate at which the IRR occurred; if no recurrence of IRR,
escalation can be resumed
If grade 3 IRR occurs, once IRR decreases to grade ≤2, restart infusion
at no more than half the rate at which IRR occurred; if no recurrence of
IRR, escalation can be resumed
Permanently discontinue in the event of life-threatening (grade 4)
IRRs at ﬁrst or at any subsequent infusion
hr. (s) hour(s), IRR infusion-related reaction, IV intravenous, min minutes
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mortality. In case of emergence of drug reactions, optimal
management is key for optimizing treatment outcome.
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